drugset / Trial / NCT03953079
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
RandomizedParallel-groupSingle-blindTreatment
Summary
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
Timeline
- Start
- 2019-09-26
- Primary completion
- 2020-12-15
- Completion
- 2021-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Sunitinib | Small molecule | 1 mg | Intravitreal |
| Subject | Sunitinib | Small molecule | 2 mg | Intravitreal |